These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 18048836)
1. Low affordability may limit the effect of cervical cancer vaccination in central and eastern European countries. Zubor P; Danko J; Kajo K; Szunyogh N J Clin Oncol; 2007 Dec; 25(34):5534-7. PubMed ID: 18048836 [No Abstract] [Full Text] [Related]
3. Prophylactic HPV vaccination for the prevention of cervical cancer. Hernandez BY Hawaii Med J; 2007 Jul; 66(7):190-1. PubMed ID: 17879858 [No Abstract] [Full Text] [Related]
4. Primary and secondary prevention of cervical cancer--opportunities and challenges. Markowitz LE; Unger ER; Saraiya M J Natl Cancer Inst; 2009 Apr; 101(7):439-40. PubMed ID: 19318638 [No Abstract] [Full Text] [Related]
5. Cost-utility analysis of vaccination against HPV in Israel. Ginsberg GM; Fisher M; Ben-Shahar I; Bornstein J Vaccine; 2007 Sep; 25(37-38):6677-91. PubMed ID: 17706844 [TBL] [Abstract][Full Text] [Related]
6. Reducing the burden of cervical cancer and HPV-related diseases through vaccination. Introduction. Cox JT Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s3-4. PubMed ID: 16520682 [No Abstract] [Full Text] [Related]
7. The economic impact of HPV vaccines: not just cervical cancer. Myers ER Am J Obstet Gynecol; 2008 May; 198(5):487-8. PubMed ID: 18455522 [No Abstract] [Full Text] [Related]
8. Mathematical models of cervical cancer prevention in the Asia Pacific region. Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411 [TBL] [Abstract][Full Text] [Related]
9. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229 [TBL] [Abstract][Full Text] [Related]
10. Towards global prevention of human papillomavirus-induced cancer. Roden RB; Gravitt P; Wu TC Eur J Immunol; 2008 Feb; 38(2):323-6. PubMed ID: 18228245 [No Abstract] [Full Text] [Related]
11. Recommendations for cervical cancer prevention in Asia Pacific. Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418 [TBL] [Abstract][Full Text] [Related]
12. [Swedish consensus on cervix cancer vaccination. Vaccination programs for eradication of HPV16/18 should be initiated in elementary schools]. Dillner J; Andrae B; Westermark B Lakartidningen; 2006 Nov 1-7; 103(44):3377-9. PubMed ID: 17152260 [No Abstract] [Full Text] [Related]
14. Who should get the HPV vaccine? Usage expands amid debate. Peres J J Natl Cancer Inst; 2010 Jun; 102(12):838-40. PubMed ID: 20530765 [No Abstract] [Full Text] [Related]
15. The new era of cervical cancer prevention: HPV vaccination. Monk BJ; Herzog TJ Gynecol Oncol; 2008 May; 109(2 Suppl):S1-3. PubMed ID: 18482553 [No Abstract] [Full Text] [Related]
16. One in four California adolescent girls have had human papillomavirus vaccination. Grant D; Kravitz-Wirtz N; Breen N; Tiro JA; Tsui J Policy Brief UCLA Cent Health Policy Res; 2009 Feb; (PB2009-3):1-6. PubMed ID: 19288623 [No Abstract] [Full Text] [Related]
17. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. Herrero R J Infect Dis; 2009 Apr; 199(7):919-22. PubMed ID: 19236278 [No Abstract] [Full Text] [Related]
18. Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer. Schauner S; Lyon C Am Fam Physician; 2010 Dec; 82(12):1541-2. PubMed ID: 21166376 [No Abstract] [Full Text] [Related]
19. Introducing HPV vaccine in developing countries--key challenges and issues. Agosti JM; Goldie SJ N Engl J Med; 2007 May; 356(19):1908-10. PubMed ID: 17494923 [No Abstract] [Full Text] [Related]